logo
Plus   Neg
Share
Email

Anacor Pharma Appoints Paul Berns As President And CEO - Quick Facts

Anacor Pharmaceuticals Inc. (ANAC) announced that its board has appointed Paul Berns, Anacor's Chairman of the Board of Directors, to assume the role of President and Chief Executive Officer, effective immediately. Berns succeeds David Perry who has served as Anacor's President and Chief Executive Officer since 2002.

Berns has over 20 years of industry experience as an executive in biotechnology and pharmaceutical companies.

Anacor said that Berns has served as a member of the company's board since 2012. From March 2006 to August 2012, Berns served as President and Chief Executive Officer, and member of the Board of Directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in August 2012.

From June 2002 to July 2005, Berns was president, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll and, from 1990 to 2000, Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Berns has been a director of Jazz Pharmaceuticals, PLC since 2010 and of XenoPort, Inc. since 2005.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT